Loading...
Loading...
CGEM| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 32.6M |
| Operating I/L | -32.6M |
| Other Income/Expense | 3.7M |
| Interest Income | 3.4M |
| Pretax | -28.9M |
| Income Tax Expense | -1.9M |
| Net Income/Loss | -27.1M |
Cullinan Oncology Inc. is a biopharmaceutical company specializing in targeted oncology and immuno-oncology therapies. Their lead candidate, CLN-081, is an orally available small molecule undergoing Phase I/IIa trials for non-small cell lung cancer. The company's pipeline also includes preclinical products such as humanized bispecific antibodies, monoclonal antibodies, fusion proteins, T cell engaging antibodies, bispecific fusion proteins, and cell therapies targeting various cancers. Cullinan Oncology generates revenue through collaboration agreements with Cullinan Pearl Corp. for the development, manufacture, and commercialization of CLN-081 and products containing CLN-081, as well as through a collaboration with Adimab, LLC for antibody discovery and optimization.
